Active Surveillance for Localized Prostate Cancer (eBook)

Laurence Klotz, MD, FRCSC, CM Professor of Surgery, University of Toronto Sunnybrook Health Sciences Centre Toronto, Ontario, Canada

Table of Contents Chapter 1        Cancer Overdiagnosis and Overtreatment                        Laurence KlotzChapter 2        Can We Screen and Still Reduce Overdiagnosis?                        Peter Ka-Fung Chiu and Monique J. RoobolChapter 3        The Role of Fear in Overdiagnosis and Overtreatment                        Iona HeathChapter 4        Ethical and Legal Considerations in Active Surveillance for Prostate Cancer                        Lionne D.F. VenderbosChapter 5        Gleason 6 Tumors Should Still Be Labeled As Cancer                        Angelo M. De Marzo and Jonathan I. EpsteinChapter 6        Risk Based Selection for Active Surveillance                        Jan F.M. Verbeek, Monique J. Roobol and Ewout W. SteyerbergChapter 7        Surveillance at the Margins: Management of High Volume Gleason 6, PSA > 10,                           or Gleason 3+4                        Laurence KlotzChapter 8        How Should Patients on Active Surveillance be Followed?                        Frank-Jan H. Drost, Monique J. Roobol, and Leonard P. BokhorstChapter 9        Triggers for Intervention                        Tuomas Mirtti, Hanna Vasarainen, and Antti RannikkoChapter 10      MR Imaging in Prostate Tumor Volume Assessment: How Accurate?                        Ivo G. Schoots and Theo H. van der KwastChapter 11      Can MRI Replace Biopsy in Men on Surveillance?                        Francesco Giganti, Vasilis Stavrinides, and Caroline M. MooreChapter 12      Tissue Based Markers for Risk Prediction                        Chad A. Reichard and Eric A. KleinChapter 13      International AS Registry:  The Movember Foundation’s Global Action Plan                                  Prostate Cancer Active Surveillance Initiative                        Sophie M. Bruinsma, Daan Nieboer, Tim Hulsen, Liying Zhang, Rachelle Kirk-                              Burnnand, Sam Gledhill, and Mark Buzza on behalf of the Movember                                            Foundation’s GAP3 Steering CommitteeChapter 14      Better Informed Decision Making to Optimize Patient Selection                        Lara Bellardita, Paola Dordoni, Letizia De Luca, Julia Paola Menichetti Delor,                               Riccardo ValdagniChapter 15      How Does QOL Compare Between Surveillance and Active Treatment?                        Lionne D.F. Venderbos, Stephanie Danielle Brandhof, and Ida J. KorfageChapter 16      The Potential Benefits of Diet and Physical Activity among Active Surveillance                            Patients with Low-Burden Prostate Cancer                        Stacey A. Kenfield, David Tat, and June M. ChanChapter 17      Is there a Role for Pharmacologic Manipulation to Prevent Progression in Men on              Active Surveillance?  The Role of 5-ARIs, Statins, and Metformin                        Roy Mano and David MargelChapter 18      The Update of Active Surveillance around the World: Utilization and Outcomes                        Jeffrey J. Tosoian, Ridwan Alam, Abbey Lepor, Stacy LoebChapter 19      Tissue Preservation – Active Surveillance and Focal Therapy as Complimentary Strategies                        Juan Gomez Rivas and Mark EmbertonChapter 20      The Economics of Active Surveillance for Prostate Cancer                        Robert B. Lurvey and Marc A. Dall’EraChapter 21      Research Questions in Active Surveillance                         Laurence Klotz